Trial Condition(s):
Non-valvular Atrial fibrillation (NVAF)
A study to evaluate the safety and effectiveness of Rivaroxaban (Xarelto) for prevention of stroke and systemic embolism in Indian patients with Non-valvular Atrial Fibrillation (NVAF) (XARIN)
Bayer Identifier:
20387
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under real-life conditions.
The study will be conducted in routine clinical practice settings.
Approximately 1000 patients from India will be enrolled in this study. Patients will be observed for maximum period of 12 months after the start of Xarelto treatment or until it is no longer possible (e.g. lost to follow-up, death, withdrawal) before the end of the observation period.
The decision by the investigator to start with of Xarelto must be independent of the inclusion of a patient to the study.
Inclusion Criteria
- Patient should be an adult female or male, ≥18 years of age; - Patient should be diagnosed with NVAF and initiated with rivaroxaban treatment for prevention of stroke or systemic embolism per investigator’s routine treatment practice; - Patient should not have received rivaroxaban in the past; - Patient/patient’s legally acceptable representative should be willing to provide written informed consent.
Exclusion Criteria
- Patient has contraindications to receive rivaroxaban therapy according to local prescribing information; - Patient is receiving anticoagulant therapy for indication other than NVAF and that needs to be continued as per discretion of treating physician; - Patient is participating in an investigational program with interventions outside of routine clinical practice.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Sunshine Hospital Secunderabad, India, 500003 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
A Real-World, Prospective, Observational Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto®) for Prevention of Stroke and Systemic Embolism in Indian Patients with Non-valvular Atrial Fibrillation (NVAF)
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Incidence of major bleeding eventsMajor bleeding events include: - Fatal bleeding - Symptomatic bleeding in a critical area or organ - Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. -- Hemoglobin level; or -- Need for transfusion of packed red blood cells or whole blood.Timeframe: Up to 18 months
- Incidence of treatment-emergent AEsTimeframe: Up to 18 months
- Incidence of treatment-emergent SAEsTimeframe: Up to 18 months
- Incidence of all-cause deathDeaths will be adjudicated as either vascular (e.g., due to stroke, embolism, myocardial infarction, or arrhythmia) or non-vascular (e.g., malignancy or infection).Timeframe: Up to 18 months
Secondary Outcome
- Incidence of symptomatic thromboembolic eventsThe date of thromboembolic events, manner in which thromboembolic events were managed in the routine practice setting, and their outcomes will be recorded. The thromboembolic events include: - Stroke and transient ischemic attack (TIA) - Systemic embolism - Myocardial infarctionTimeframe: Up to 18 months
- Non-major bleeding eventsThe date of non-major bleeding events, treatment approaches employed during non-major bleeding events, and the associated outcomes will be collected.Timeframe: Up to 18 months
- AE rates in the different NVAF risk factor categoriesRates of AEs across patients with different baseline risk profiles for stroke or bleeding calculated using Congestive heart failure, Hypertension, Age, Diabetes mellitus, Stroke(CHADS2), Vascular disease, Age, Sex category (CHA2DS2-VASc), or Hypertension, Abnormal liver/renal function, Stroke history, Bleeding predisposition, Labile international normalized ratios, Elderly, Drug/alcohol usage (HAS-BLED).Timeframe: Up to 18 months
- SAE rates in the different NVAF risk factor categoriesRates of SAEs across patients with different baseline risk profiles for stroke or bleeding calculated using Congestive heart failure, Hypertension, Age, Diabetes mellitus, Stroke (CHADS2), Vascular disease, Age, Sex category (CHA2DS2-VASc), or Hypertension, Abnormal liver/renal function, Stroke history, Bleeding predisposition, Labile international normalized ratios, Elderly, Drug/alcohol usage (HAS-BLED).Timeframe: Up to 18 months
- Treatment persistence with rivaroxabanTreatment persistence with rivaroxaban therapy will be defined as the absence of a gap of >60 days between two doses of rivaroxaban, without any switch to alternative anticoagulant. Reasons for any switch from or interruption of rivaroxaban therapy during the observation period will be collected and summarized.Timeframe: Up to 18 months
Additional Information
Copyright © Bayer
Powered by
